Statins Added to Beta-Blockers Cut Mortality in Compensated Cirrhosis
This meta-analysis isolates the incremental effect of adding statins to non-selective beta-blocker therapy in portal hypertension, informing adjunctive pharmacotherapy decisions for hepatology pharmacists.
📅 Journal publication: Jul 19, 2026·Last updated: Oct 8, 2026
Statins may lower mortality in cirrhosis with portal hypertension.
Patients with cirrhosis and portal hypertension remain at high risk despite using non-selective beta-blockers, and adding statins may enhance treatment efficacy. Adding statins to non-selective beta-blockers reduced all-cause mortality (relative risk (RR) = 0.46), but did not clearly decrease complications like variceal bleeding or ascites. Though statins improved portal hemodynamics, their effect on specific portal hypertension-related complications is unclear, highlighting the need for further research before widespread implementation. Statins added to non-selective beta-blockers may reduce mortality in cirrhotic patients with portal hypertension.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Wu Q, Yang Y, Wu Q, et al. Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials. Annals of hepatology. 2026;31(2):102259. doi:10.1016/j.aohep.2026.102259
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.